NCT01650636

Brief Summary

The purpose of this study is to test the effects of a videotelephone-delivered patient-partner dual-focused cognitive behavioral stress management intervention on chronic fatigue syndrome (CFS) symptoms and related psychosocial and neuroimmune processes in patients diagnosed with chronic fatigue syndrome. Study tests the hypothesis that videophone-delivered patient-partner cognitive behavioral stress management (T-PP-CBSM) intervention improves patient CFS symptoms relative to a videophone-delivered patient-partner Health Information (PP-T- HI) condition.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

July 23, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 26, 2012

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

July 18, 2018

Completed
Last Updated

December 10, 2018

Status Verified

December 1, 2018

Enrollment Period

6.6 years

First QC Date

July 23, 2012

Results QC Date

April 26, 2018

Last Update Submit

December 6, 2018

Conditions

Keywords

Videophone-delivered stress management interventionChronic fatigue syndromeSymptomsNeuroimmune processesPsychosocial

Outcome Measures

Primary Outcomes (2)

  • Changes in Frequency and Severity of CDC-based CFS Symptoms

    Changes in the average frequency and average severity ratings of CFS symptoms as assessed by the CDC Symptom Inventory. Participants rated the frequency (1: A little of the time to 5: All of the time) and severity (1: Very mild to 5: Very severe) of individual CFS symptoms. Greater units on the scale indicate greater symptom frequency or severity. The outcome measure was calculated as a set of two composite scores: 1) Average Symptom Frequency, reflecting an aggregated average of frequency across all symptoms, and 2) Average Symptom Severity, reflecting an aggregated average of severity across all symptoms. Change scores are expressed and calculated as Follow-Up minus Baseline scores for average symptom frequency and average symptom severity.

    baseline and 5 and 9 month post-intervention follow-up

  • Changes in a Single Composite Product of Average Frequency and Severity Scores of CDC-based CFS Symptoms

    Changes in the composite product of average frequency and severity scores of CDC-based CFS symptoms assessed by the CDC Symptom Inventory. Participants rated the frequency (1: A little of the time to 5: All of the time) and severity (1: Very mild to 5: Very severe) of individual CFS symptoms. Greater units on the scale indicate greater symptom frequency or severity. The composite outcome measure was calculated as the product of Average Symptom Frequency and Average Symptom Severity. Change scores are expressed and calculated as Follow-Up minus Baseline scores for the composite product score.

    baseline and 5 and 9 months post-intervention follow-up

Secondary Outcomes (5)

  • Changes in Neuroimmune Functioning Measured by Change in Averaged (2-day) Di-urnal Slope of Salivary Cortisol.

    baseline and 5 and 9 month post-intervention follow-up

  • Changes in Neuroimmune Functioning Measured by Pro-Inflammatory Cytokines

    Baseline, 5 months, 9 months

  • Changes in Neuroimmune Functioning Measured by Anti-inflammatory Cytokines

    Baseline, 5 months, 9 months

  • Changes in Neuroimmune Regulation Measured by Ratio of Pro-Inflammatory to Anti-Inflammatory Cytokines

    baseline and 5 and 9 months post-intervention follow-up

  • Changes in Psychosocial Functioning

    baseline and 5 and 9 month post-intervention follow-up

Study Arms (2)

Cognitive Behavioral Stress Management

EXPERIMENTAL
Behavioral: Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)

Health Information

ACTIVE COMPARATOR
Behavioral: Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)

Interventions

Ten (10) 90-min sessions of Health Information delivered via videophones

Health Information

Ten (10) 90-min sessions of T-PP-CBSM

Cognitive Behavioral Stress Management

Eligibility Criteria

Age21 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • men and women diagnosed with chronic fatigue syndrome

You may not qualify if:

  • no partner
  • prior psychiatric treatment for serious psychiatric disorder (e.g., psychosis, suicidality)
  • co-morbidity or medical treatment affecting the immune system
  • lack of fluency in English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Psychology University of Miami

Coral Gables, Florida, 33124, United States

Location

Related Publications (1)

  • Milrad SF, Hall DL, Jutagir DR, Lattie EG, Czaja SJ, Perdomo DM, Ironson G, Doss BD, Mendez A, Fletcher MA, Klimas N, Antoni MH. Relationship satisfaction, communication self-efficacy, and chronic fatigue syndrome-related fatigue. Soc Sci Med. 2019 Sep;237:112392. doi: 10.1016/j.socscimed.2019.112392. Epub 2019 Jul 16.

MeSH Terms

Conditions

Fatigue Syndrome, Chronic

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesEncephalomyelitisNeuroinflammatory DiseasesNervous System DiseasesNeuromuscular DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Dr. Michael Antoni
Organization
University of Miami

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

July 23, 2012

First Posted

July 26, 2012

Study Start

October 1, 2010

Primary Completion

May 1, 2017

Study Completion

May 1, 2017

Last Updated

December 10, 2018

Results First Posted

July 18, 2018

Record last verified: 2018-12

Locations